Summary
For millions of people living with glaucoma, lowering eye pressure remains the cornerstone of treatment. Yet many patients continue to lose vision despite successful pressure control.
A randomized clinical trial conducted by researchers at Columbia University found that a combination of nicotinamide (a form of vitamin B3) and pyruvate (a naturally occurring energy-producing molecule) may improve visual function in people with open-angle glaucoma. While the findings are preliminary and short-term, they provide some of the strongest human evidence yet that targeting the eye's energy metabolism could help protect vulnerable retinal nerve cells.
Key Takeaways
- A Phase 2 randomized clinical trial tested oral nicotinamide and pyruvate in patients with treated open-angle glaucoma.
- Patients receiving the supplements showed significantly more improvement in visual field sensitivity than those receiving placebo.
- The treatment appeared safe, with no serious adverse events reported.
- Researchers believe the supplements may support the energy needs of retinal ganglion cells, the nerve cells damaged in glaucoma.
- The study lasted only about two months, so it does not prove that the supplements slow long-term vision loss.
- Larger and longer studies are needed before these supplements can become part of standard glaucoma care.
Why This Study Matters
Glaucoma is often called the "silent thief of sight" because it can slowly damage vision without noticeable symptoms until substantial loss has already occurred.
Most glaucoma treatments focus on lowering intraocular pressure (IOP)—the pressure inside the eye. While pressure reduction is highly effective, many patients continue to experience disease progression even when their eye pressure is well controlled.
That reality has fueled a decades-long search for treatments that do more than lower pressure. Scientists have increasingly focused on neuroprotection—strategies designed to protect retinal ganglion cells, the nerve cells that carry visual information from the eye to the brain.
This new study is important because it tests a novel idea: instead of targeting eye pressure, can we improve the health and function of retinal nerve cells by improving their energy supply?
The Biological Rationale: Glaucoma May Be an Energy Crisis
Recent laboratory research has revealed that retinal ganglion cells in glaucoma may suffer from mitochondrial dysfunction.
Mitochondria are often described as the cell's "power plants." They generate the energy required for normal cellular function. Studies in animal models have shown that glaucoma is associated with declining levels of:
- Nicotinamide adenine dinucleotide (NAD+), a molecule essential for cellular energy production.
- Pyruvate, a key fuel source used in cellular metabolism.
Researchers found that restoring these molecules protected retinal ganglion cells from degeneration in mice and rats.
Nicotinamide serves as a precursor to NAD+, while pyruvate helps cells generate energy and may also function as an antioxidant. Together, the two compounds appeared particularly effective in animal studies, leading investigators to test them in humans.
Study Design
Type of Study
This was a:
- Phase 2 clinical trial
- Randomized
- Double-blind
- Placebo-controlled
These features represent the gold standard for evaluating potential treatments because neither patients nor investigators know who receives active treatment.
Participants
Researchers screened 197 individuals and enrolled 42 patients with:
- Open-angle glaucoma
- Moderate visual field loss
- Stable treatment with pressure-lowering medications
Thirty-two participants completed the study and were included in the final analysis.
Average age was approximately 65 years, and about two-thirds of participants were women.
What Treatment Did Patients Receive?
Participants were randomly assigned in a 2:1 ratio to receive either:
Active Treatment
- Nicotinamide:
- 1,000 mg daily initially
- Increased to 3,000 mg daily
- Pyruvate:
- 1,500 mg daily initially
- Increased to 3,000 mg daily
Placebo
Participants in the control group received matching placebo tablets.
The study lasted a median of approximately 2.2 months.
How Did Researchers Measure Success?
The primary outcome focused on changes in the visual field.
What Is a Visual Field Test?
Visual field testing measures how well a person sees throughout their entire field of vision, including peripheral vision.
Glaucoma often causes blind spots that begin in the peripheral field before progressing toward central vision.
The researchers used the Humphrey Visual Field Analyzer, one of the most widely used tools in glaucoma care.
Understanding the Key Measurements
Mean Deviation (MD)
Measures overall visual field loss compared with healthy individuals.
- More negative values indicate worse vision.
Pattern Standard Deviation (PSD)
Measures irregularities in the visual field.
- Higher values generally indicate more localized glaucoma damage.
Visual Field Index (VFI)
A percentage-based estimate of remaining visual function.
- 100% represents a normal visual field.
- Lower percentages indicate greater damage.
The Primary Endpoint
Researchers counted how many individual test points in the visual field improved beyond what would normally be expected from test-to-test variability.
This approach helps distinguish genuine functional improvement from random fluctuations.
What Did the Researchers Find?
The results were encouraging.
More Areas of Visual Improvement
Patients receiving nicotinamide and pyruvate had significantly more improving visual field locations than those receiving placebo.
- Treatment group: median 15 improving locations
- Placebo group: median 7 improving locations
Statistical analysis suggested that treated eyes were approximately three times more likely to experience meaningful improvement.
Improvement in Pattern Standard Deviation
The treatment group showed significantly better changes in PSD, suggesting improved visual function.
Trends Toward Better Overall Vision
Mean deviation and visual field index did not reach statistical significance, but both moved in a direction favoring treatment.
No Serious Safety Concerns
No serious adverse events were reported.
The most common side effect was mild gastrointestinal discomfort, which occurred at similar rates in both groups and generally resolved without intervention.
Why These Findings Matter
One of the most intriguing observations was where improvement occurred.
The visual field locations that improved tended to be areas with mild to moderate damage, rather than areas that were completely normal or severely damaged.
This finding supports a fascinating hypothesis.
Researchers believe some retinal ganglion cells in glaucoma may not be dead but instead function poorly because of metabolic stress and insufficient energy production. By restoring cellular energy pathways, nicotinamide and pyruvate may help these struggling cells function more effectively.
In other words, the treatment may be helping "sick" nerve cells recover rather than regenerating cells that have already been lost.
If confirmed, this would represent a fundamentally new treatment strategy for glaucoma.
What Are the Limitations?
Although promising, the study should not be interpreted as proof that nicotinamide and pyruvate prevent blindness.
Several important limitations remain:
Short Duration
Participants were followed for only about two months.
Glaucoma is a lifelong disease that progresses slowly over years.
Small Sample Size
Only 32 participants completed the trial.
Larger studies are needed to confirm the findings.
Functional Improvement vs. Disease Modification
The study demonstrated short-term improvement in visual function.
It did not establish whether the supplements can slow long-term progression of glaucoma.
Structural Changes Were Not Proven
Optical coherence tomography (OCT) measurements did not show statistically significant changes in retinal nerve fiber layer thickness.
The Bigger Picture
For decades, glaucoma treatment has centered almost entirely on lowering eye pressure.
This study represents a growing movement toward treating glaucoma as a disease of neuronal energy failure and mitochondrial dysfunction.
The findings suggest that nutritional and metabolic therapies may someday complement conventional pressure-lowering treatments.
While patients should not replace prescribed glaucoma medications with supplements based on this study alone, the research offers an exciting glimpse into what the future of glaucoma care may look like: protecting and revitalizing retinal nerve cells before vision is permanently lost.
Bottom Line
A Phase 2 clinical trial found that high-dose nicotinamide and pyruvate produced measurable short-term improvements in visual function among patients with treated open-angle glaucoma.
The treatment was generally well tolerated and supports the growing theory that glaucoma involves an energy deficit within retinal nerve cells. Although larger and longer studies are still needed, the results provide some of the most compelling human evidence to date that metabolic therapies may one day become an important addition to glaucoma treatment.
Study Reference
De Moraes CG, John SWM, Williams PA, Blumberg DM, Cioffi GA, Liebmann JM. Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2022 Jan 1;140(1):11-18. doi: 10.1001/jamaophthalmol.2021.4576. PMID: 34792559; PMCID: PMC8603231.
Science-informed glaucoma supplement with 500 mg Nicotinamide & 120 mg Ginkgo Biloba. Be first to know when it's available.
